BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19252387)

  • 1. [Consideration on molecular imaging technology as a tool for drug research and development].
    Yajima K; Nishimura S
    Yakugaku Zasshi; 2009 Mar; 129(3):297-304. PubMed ID: 19252387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular imaging-based early-phase and exploratory clinical research].
    Watanabe Y
    Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
    Bergström M; Grahnén A; Långström B
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):357-66. PubMed ID: 12937873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of PET radiopharmaceuticals at the academia-industry interface.
    Bernard-Gauthier V; Collier TL; Liang SH; Vasdev N
    Drug Discov Today Technol; 2017 Nov; 25():19-26. PubMed ID: 29233263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
    Burt T; John CS; Ruckle JL; Vuong LT
    Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective use of microdosing and Positron Emission Tomography (PET) studies on new drug discovery and development.
    Sugiyama Y
    Drug Metab Pharmacokinet; 2009; 24(2):127-9. PubMed ID: 19430167
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery.
    Zimmer L
    Expert Opin Drug Discov; 2024 Feb; 19(2):161-172. PubMed ID: 37948046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging as a tool in drug development.
    Strack T
    Drugs Today (Barc); 2007 Oct; 43(10):725-36. PubMed ID: 17987225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging devices for use in small animals.
    Koba W; Kim K; Lipton ML; Jelicks L; Das B; Herbst L; Fine E
    Semin Nucl Med; 2011 May; 41(3):151-65. PubMed ID: 21440693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development.
    Burt T; Vuong LT; Baker E; Young GC; McCartt AD; Bergstrom M; Sugiyama Y; Combes R
    Altern Lab Anim; 2018 Dec; 46(6):335-346. PubMed ID: 30657329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
    Roselt P; Meikle S; Kassiou M
    Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosing and drug development: past, present and future.
    Lappin G; Noveck R; Burt T
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging in the cardiovascular and metabolic disease area.
    Comley RA; Kallend D
    Drug Discov Today; 2013 Feb; 18(3-4):185-92. PubMed ID: 23032726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
    Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.